Mutagen Sensitivity (MS) May Predict Lung Protection by Amifostine for Patients with Locally Advanced Non-Small Cell Lung Cancer (NSCLC) Treated by Chemoradiotherapy

R Komaki,MR Spitz,X Wu,JY Chang,PK Allen,M Lika,FV Fossella,CW Stevens,Z Liao,JD Cox

DOI: https://doi.org/10.1053/j.seminoncol.2005.03.016

IF: 45.3

2004-01-01

Journal of Clinical Oncology

Abstract:7232 Background: Amifostine (AMF) has been shown to protect some normal tissues from acute effects of radiation therapy ± chemotherapy. We enrolled 62 pts in a randomized study investigating the efficacy of AMF: 31 had concurrent chemoradiation for NSCLC and 31 had the same treatment + AMF. AMF reduced the severity or frequency of esophagitis, pneumonitis and neutropenic fever. It was hypothesized that DNA repair capacity could predict outcome. Methods: Forty-six out of the 62 pts provided pretreatment blood for assessment of MS using a peripheral lymphocyte assay that infers DNA repair capacity from cellular damage remaining after in vitro mutagenic exposure and recovery. Bleomycin-induced chromosome breaks in 50 metaphases were counted and expressed as the mean number of breaks/cell. Pts with an average of >1 break/cell were deemed to exhibit the MS phenotype. Data analysis used Pearson's chi square and Kaplan-Meier survival function estimates with Strata 8.2 statistical software. The Log Rank test was used to assess the equality of survival function using a p-value of 0.05. Results: Twelve patients (10 AMF, 2 control) exhibited the MS phenotype. The remaining 34 pts (13 AMF, 21 control) were considered to have normal DNA repair. There were no significant differences in overall survival, disease specific survival, or local control by MS. Those with MS had shorter distant metastasis-free survival (DMFS) compared to nonsensitive pts (p=0.029). There were no differences in severe esophagitis or neutropenic fever by MS. Both MS pts from the control group developed severe lung fibrosis compared with 5 of 21 who did not have MS (p=0.025). The incidence of grade 3–4 lung fibrosis was 2/10 with AMF compared with 2/2 in the control group (p=0.025) with MS. Conclusions: MS was associated with shorter DMFS and more frequent Gr 3–4 lung fibrosis. AMF reduced the incidence of Gr 3–4 lung fibrosis. These data suggest that MS might help identify subgroups of pts who could derive benefit from AMF with respect to lung damage. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration MedImmune